Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Mult Scler.

Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P

doi: 10.1177/1352458519881759.

Aging and Cognitive FunctionsMultiple Sclerosis

Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

Mult Scler.

Benedict RH, Cohan S, Lynch SG, Riester K, Wang P, Castro-Borrero W, Elkins J, Sabatella G

doi: 10.1177/1352458517707345.

Multiple Sclerosis

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study

PLoS One.

Izquierdo G, Damas F, Páramo MD, Ruiz-Peña JL, Navarro G

doi: 10.1371/

Multiple Sclerosis

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

N Engl J Med.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L

doi: 10.1056/NEJMoa1601277.

Multiple Sclerosis

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis

Mult Scler Relat Disord.

Liu Y, Vollmer T, Havrdova E, Riester K, Lee A, Phillips G, Wang P, Sabatella G

doi: 10.1016/j.msard.2016.11.005.

RECOMMENDED

Multiple Sclerosis

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Lancet Neurol.

Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI, SYNERGY study investigators.

doi: 10.1016/S1474-

Multiple Sclerosis

Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program

Mult Scler.

Wiendl H, Spelman T, Butzkueven H, Kappos L, Trojano M, Su R, Campbell N, Ho PR, Licata S

doi: 10.1177/1352458520926869.

Related content

Vaccination Readiness in Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program